Protara Therapeutics Announces Inducement Stock Awards
Protara Therapeutics, Inc. (Nasdaq: TARA) is thrilled to share the exciting news about the granting of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. This pivotal moment reflects Protara’s commitment to attracting top talent as it continues its mission to develop transformative therapies for cancer and rare diseases.
Details of the Inducement Grants
The Compensation Committee of Protara’s Board of Directors approved an aggregate of 29,500 stock option awards alongside 14,750 RSU awards awarded to two new team members from the Inducement Plan. These inducement grants play a crucial role in the employees’ transition into the company, which aligns with Nasdaq Listing Rule 5635(c)(4). The stock options were granted with an exercise price aligned with Protara’s closing trading price, which was $2.80 per share on the grant date.
Vesting Schedule for Stock Options and RSUs
With a structured approach to investing in its employees, all stock option awards are set to vest over a period of four years. Specifically, 25% of the underlying shares will vest on the one-year anniversary of the option grant, with the remaining shares vesting incrementally over the subsequent months. On the other hand, the RSUs will vest over three years, with one-third of the shares becoming available to employees each year on the anniversary of the grant date. Importantly, the vesting of these awards hinges on the employee’s continued service with the company.
About Protara Therapeutics, Inc.
As a dedicated clinical-stage biotechnology company, Protara Therapeutics is transforming the landscape of therapies aimed at treating cancer and rare diseases. At the forefront of its portfolio is TARA-002, an innovative cell-based therapy targeting non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). Currently, Protara is conducting a Phase 2 trial of TARA-002 for NMIBC patients, specifically those with carcinoma in situ (CIS) who have had limited responses to Bacillus Calmette-Guérin (BCG) treatment.
Further Advancements in Treatment
Moreover, the company is also focusing on pediatric trials for LMs, emphasizing its holistic approach towards diverse treatment needs. Additionally, Protara has developed IV Choline Chloride, which serves as a phospholipid substrate replacement aimed at patients requiring parenteral nutrition, thus enhancing their quality of life.
Connect with Protara Therapeutics
For those seeking more information on Protara Therapeutics and its groundbreaking work in biotechnology, the official website www.protaratx.com offers comprehensive details about its research initiatives and offerings.
Company Contact Information
For inquiries, individuals can reach out to Justine O'Malley at Protara Therapeutics via email at Justine.OMalley@protaratx.com or call at 646-817-2836.
Frequently Asked Questions
What is the significance of the inducement grants?
The inducement grants are designed to attract and retain talented individuals, thereby enhancing the company’s capabilities and fostering innovation.
How many stock options and RSUs were granted?
A total of 29,500 stock options and 14,750 RSUs were granted to two new employees.
What is the exercise price for the stock options?
The exercise price for the stock options is $2.80 per share, reflecting the company’s closing trading price at the time of grant.
What is Protara's lead candidate?
TARA-002 is Protara's lead candidate, which is an investigational therapy aimed at treating non-muscle invasive bladder cancer and lymphatic malformations.
How can I learn more about Protara Therapeutics?
To learn more about Protara and its initiatives, please visit the official website at www.protaratx.com.
